KRAS and TP53 somatic mutations associate with the expression changes of spot B, which harbors both genes in its neighborhood, acting in opposite directions, however, namely in up- and downregulation, respectively, which is in accordance with the major functions of KRAS as oncogene and of TP53 as a tumor suppressor. The gene discussed is KRAS; the disease is neoplasm.